Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world radiology data for artificial intelligence-driven cancer support systems and biomarker development.

ESMO real world data and digital oncology·2026
Same author

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

ESMO open·2024
Same author

Clinical, radiological, and molecular diagnosis of congenital pituitary diseases causing short stature.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2023
Same author

Anesthesia management in a patient with Churg-Strauss syndrome in the ambulatory setting: A case report.

Revista espanola de anestesiologia y reanimacion·2023
Same author

Associations between food portion sizes, insulin resistance, VO2 max and metabolic syndrome in European adolescents: The HELENA study.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2022
Same author

Penetrating cardiac trauma caused by a nail-gun: A case report and narrative review.

Trauma case reports·2022

Related Experiment Video

Updated: Jun 21, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

[Experimental models in Alzheimer's disease].

S Manzano1, Jl González, A Marcos

  • 1Servicio de Neurología, Instituto Neurociencias, Hospital Clinico San Carlos, Madrid.

Neurologia (Barcelona, Spain)
|July 16, 2009
PubMed
Summary

Experimental models are crucial for understanding Alzheimer's disease (AD) and developing new therapies. Research reviews various animal and cellular models, aiding in the development of novel therapeutic strategies for AD.

More Related Videos

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Related Experiment Videos

Last Updated: Jun 21, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Area of Science:

  • Neurodegenerative disease research
  • Alzheimer's disease (AD) pathology
  • Experimental modeling in neuroscience

Context:

  • Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, accounting for 60-80% of cases.
  • Accurate diagnosis of AD relies on studying brain pathology.
  • Since the 1970s, experimental models have significantly advanced AD research and therapeutic development.

Purpose:

  • To review existing literature on experimental models of Alzheimer's disease (AD).
  • To identify and categorize diverse experimental models used in AD research.
  • To explore novel therapeutic approaches derived from these models.

Summary:

  • A comprehensive review of experimental models for Alzheimer's disease (AD) was conducted using PubMed.
  • Models reviewed include those based on amyloid precursor protein (APP), Presenilin (PS), tau protein, neprilysin, and APOE.
  • Various animal models (rodents, primates, etc.) and cell-based systems (hippocampal neurons) are discussed, including their relevance to AD pathology and Abeta oligomers.

Impact:

  • Experimental models are indispensable tools for deepening the understanding of neurodegenerative diseases, particularly AD.
  • These models facilitate the design and testing of innovative therapeutic strategies for Alzheimer's disease.
  • Advancements in experimental modeling accelerate the discovery of potential treatments for AD.